|
Dementia
|
0.100 |
Biomarker
|
disease |
BEFREE |
<b>Methods:</b> We enrolled 107 participants (45 amyloid-β-negative cognitively unimpaired [CU-], 7 amyloid-β-positive cognitively unimpaired [CU+], 31 with prodromal AD [mild cognitive impairment; MCI+], and 24 with AD dementia [DEM+]) who completed 2 baseline PET scans (<sup>18</sup>F-flortaucipir and <sup>18</sup>F-florbetaben), MRI, and neuropsychologic tests.
|
30926651 |
2019 |
|
Dementia
|
0.100 |
Biomarker
|
disease |
BEFREE |
A multivariate model based on the Disease State Index classifier incorporated the available baseline tests to predict progression to MCI or dementia over time.
|
30619929 |
2018 |
|
Dementia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Simultaneous multi-category classification analyses showed that the volume under the ROC surface (VUS) was 0.57 and that the derived optimal cut-off points were 2 and 8 for controls, MCI, and dementia.
|
29475235 |
2018 |
|
Dementia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Within four years, 42 (22.8%) MCI individuals in the clinical sample and 45 (10.3%) individuals in the population-based sample progressed to dementia.
|
29335040 |
2018 |
|
Dementia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Imaging findings and dementia/MCI biomarkers provide preliminary evidence for an indirect association of the two conditions.
|
29232279 |
2018 |
|
Dementia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Age (hazard ratio (HR) 1.05 per year, 95% CI: 1.01-1.08, p = 0.007), presence of MCI status (HR 3.40, 95% CI: 1.97-6.92, p < 0.001), MTA (HR 1.71 per point, 95% CI: 1.26-2.32, p = 0.001), and SVD score (HR 1.23 per point, 95% CI: 1.20-1.48, p = 0.030) at baseline were independent predictors for dementia conversion in these patients.
|
28318355 |
2018 |
|
Dementia
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Further analysis of the diagnostic subgroups suggested different variables were more strongly associated with IADL from group to group (apathy and depression for normal participants, apathy for MCI participants and for participants with dementia due to AD, but not for those with non-AD dementia).
|
29190312 |
2018 |
|
Dementia
|
0.100 |
Biomarker
|
disease |
BEFREE |
<b>Conclusions:</b> Linguistic features of spontaneous speech transcribed and analyzed by NLP techniques show significant differences between controls and pathological states (not only eD but also MCI) and seems to be a promising approach for the identification of preclinical stages of dementia.
|
30483116 |
2018 |
|
Dementia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Cognitive decline (defined as the incidence of either Parkinson's disease mild cognitive impairment [PD-MCI] or dementia [PDD], diagnosed according to published criteria and blinded to genotype) was studied as the primary outcome.
|
28869277 |
2018 |
|
Dementia
|
0.100 |
Biomarker
|
disease |
BEFREE |
The primary outcome was cognitive status, classified as normal, mild cognitive impairment [MCI], and dementia on the basis of standardized cognitive tests (delayed word recall, word fluency, and digit symbol substitution).
|
30030736 |
2018 |
|
Dementia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Associations between CSF cortisol and CSF norepinephrine in cognitively normal controls and patients with amnestic MCI and AD dementia.
|
29446123 |
2018 |
|
Dementia
|
0.100 |
Biomarker
|
disease |
BEFREE |
AD diagnosis (MCI or dementia) with normal CSF biomarkers is a rare condition.
|
29318973 |
2018 |
|
Dementia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Prevalence of amyloid positivity in the Olmsted County population without dementia and risk of progression from no cognitive impairment (ie, normal cognition for age) to incident amnestic MCI (aMCI) and from MCI or aMCI to incident AD dementia.
|
29710225 |
2018 |
|
Dementia
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
It is expected that future versions of cognitive screening tests, modified using a PBA, will highlight the benefits of attending to qualitative features of test performance when trying to identify subtle features suggestive of MCI and/or dementia.
|
29113605 |
2018 |
|
Dementia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Fine-Gray subdistribution modeling was used to examine the risk of progression from CN to MCI/dementia due to Aβ+, APOEɛ4 carriage, and their interaction in the Australian Imaging, Biomarkers and Lifestyle (AIBL) flagship study of aging CN cohort (n = 599) over 8 years.
|
30149452 |
2018 |
|
Dementia
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The cross-sectional cohort included control subjects without dementia and patients with AD, and the longitudinal cohort included patients with MCI and patients with AD followed over a 2-year period.
|
29378650 |
2018 |
|
Dementia
|
0.100 |
Biomarker
|
disease |
BEFREE |
We analyzed 94 patients with MCI-AD followed until conversion to dementia and 39 patients with MCI who had brain amyloidosis (AMY+ MCI), all with available baseline <sup>18</sup>F-fluorodeoxyglucose positron emission tomography (FDG-PET) results.
|
29615111 |
2018 |
|
Dementia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Furthermore, high vascular risk was identified as a potential predictor of both MCI and dementia in PD.
|
29572571 |
2018 |
|
Dementia
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Seventy-seven individuals with pre-MCI and 180 CN elders were recruited from the pool of individuals registered at the National Research Center for Dementia in Gwangju, Korea.
|
30176706 |
2018 |
|
Dementia
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
In a follow-up analysis using an independent data set, we demonstrate a protective effect of this variant against risk of conversion to MCI or AD (p = 0.038) and against cognitive decline in individuals who develop dementia (p = 3.41 × 10<sup>-15</sup> ).
|
29130521 |
2017 |
|
Dementia
|
0.100 |
Biomarker
|
disease |
BEFREE |
The Q mci-TR is a reliable and useful screening tool for discriminating MCI from SMC and dementia in a Turkish population.
|
28423938 |
2017 |
|
Dementia
|
0.100 |
Biomarker
|
disease |
BEFREE |
A high prevalence of MCI or dementia was observed in the elderly population.
|
28769097 |
2017 |
|
Dementia
|
0.100 |
Biomarker
|
disease |
BEFREE |
One hundred and seven elderly subjects with cognitive impairment (91 memory clinic patients with mild cognitive impairment [MCI] and 16 with dementia of AD type) and 55 cognitively healthy volunteers were included in this study.
|
29054536 |
2017 |
|
Dementia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Higher stride time variability was associated with falls in older adults without dementia (CHI and each MCI subgroup) and mild non-AD dementia, whereas lower gait speed was associated with falls in all participant groups, except in mild AD dementia.
|
27914848 |
2017 |
|
Dementia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Individuals who were married and those who were very satisfied with life are protected against the risk of developing MCI and dementia.
|
28269770 |
2017 |